Caspr1 antibodies autoimmune paranodopathy with severe tetraparesis: potential relevance of antibody titers in monitoring treatment response.

Our patient had a severe progressive course with early disability and axonal damage, and slow recovery starting only a few months after antibody-depleting therapy. The close correlation between titer, disability and treatment, supports the pathogenicity of Caspr1 antibodies, and suggest that their longitudinal evaluation might provide a potential biomarker to evaluate treatment response. This article is protected by copyright. All rights reserved.